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Abstract
Background Xanthine oxidase (XO) inhibitors are largely
the treatment of choice for gout, but allopurinol is often
inappropriately used for asymptomatic hyperuricemia.
There is little evidence that allopurinol is useful in pre-
venting cardiovascular diseases and therapeutic decisions
must the balance the expected benefit with the potential
harm.
Objective To investigate the appropriateness of XO
inhibitor use in relation to evidence-based indications and
examine the role of community pharmacies in the detection
of inappropriate prescriptions of these drugs.
Methods This is an observational study conducted in
eight community pharmacies. Each pharmacist was asked
to interview a sample of patients who had received pre-
scriptions of XO inhibitors. Patients were asked to com-
plete a structured minimum data set that collected
information on drug indication, history of gout, and pres-
ence of cardiovascular diseases.
Results The study sample included 74 patients receiving
XO inhibitors. About one third of patients reported being
treated for asymptomatic hyperuricemia and had never
had a gout attack. About half of the patients treated for
asymptomatic hyperuricemia had been receiving the drug
treatment for more than 3 years. Four asymptomatic
hyperuricemic patients received allopurinol to treat hy-
pertension. Among the patients treated for asymptomatic
hyperuricemia, there was a higher presence of diabetes
mellitus, obesity, previous myocardial infarction, and
heart failure than in patients treated for an appropriate
indication.
Conclusions Inappropriate use of XO inhibitors is prin-
cipally related to the treatment of hyperuricemia in patients
with cardiovascular diseases. Community pharmacists have
a central role in pharmacovigilance, by contributing to the
prevention and identification of potentially inappropriate
drug prescriptions.
Members of Study Group of Community Pharmacists (SGCP)
Investigators are listed in Appendix.
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Key Points
Xanthine oxidase (XO) inhibitors are largely the
treatment of choice for gout, but allopurinol is often
inappropriately used for asymptomatic
hyperuricemia. There is little evidence that
allopurinol is useful in preventing cardiovascular
diseases and therapeutic decisions must balance the
expected benefit with the potential harm.
In Italy, allopurinol is not prescribed according to
guidelines, thus exposing patients to an increased
risk of adverse drug reactions. Inappropriate use of
XO inhibitors is principally related to the treatment
of hyperuricemia in patients with cardiovascular
diseases, although there is little evidence that
allopurinol is useful in preventing cardiovascular
diseases.
Community pharmacies could contribute to the
prevention and identification of potentially
inappropriate drug prescriptions.
Introduction
Xanthine oxidase (XO) inhibitors are the principal treatment
of choice for gout, and allopurinol is used by more than 1.2
million patients in the USA and UK. However, this drug is
often inappropriately used in asymptomatic hyperuricemia
[1], and this indication is not supported by conclusive evi-
dence from prospective, randomized, clinical human
research trials, nor is it recommended by any guidelines [2].
The culprit in gout is the accumulation of uric acid in joints.
Uric acid is formed mainly by the enzyme XO, which
converts hypoxanthine and oxygen into uric acid, superox-
ide, and other oxidative-free radicals [3]. It is therefore clear
that inhibiting XO will reduce uric acid and, hence the
tendency for gout [4]. Inhibition of XO and the consequent
production of harmful oxidative metabolites has been
associated with other clinical benefits of allopurinol:
improvement in endothelial/vascular dysfunction; reduction
of vascular tissue oxidative stress; increase in adenosine
triphosphate/energy, and oxygenation of ischemic tissues
[3]. Allopurinol has therefore been suggested to be poten-
tially useful in different conditions: prevention or regression
of atherosclerosis; prevention of cardiovascular (CV) events
in patients after an acute coronary syndrome or myocardial
infarction, transient ischemic attack, cerebral vascular
accident, or intermittent claudication, and reduction of heart
failure after myocardial infarction [5]. However, there is
little evidence for a role of allopurinol in the prevention of
CV diseases and the debate on its role in asymptomatic
hyperuricemic patients is still open. Only two epidemiologic
and experimental studies (one in patients with heart failure
and one in hyperuricemic patients) have suggested a link
between hyperuricemia, hypertension, and reduced total
mortality [6, 7], and two small randomized controlled trials
found that allopurinol reduced CV events [8, 9]. However,
treating asymptomatic hyperuricemia has no clear benefit
because allopurinol hypersensitivity syndrome is rare and
often occurs as a consequence of inappropriate drug use
[10]. Therapeutic decisions must therefore balance the
expected benefit with the potential harm.
Similarly, febuxostat is a new, potent non-purine-
selective inhibitor of XO and is now recommended as the
first-line pharmacologic urate-lowering therapy for gout in
the American College of Rheumatology guidelines [2].
However, although it achieves more selective, potent, and
persistent XO inhibition and greater hypouricemic activity
than allopurinol, there is no evidence of CV benefits [11].
According to the hypothesis that inappropriate pre-
scription is associated with the treatment of asymptomatic
hyperuricemia in patients with CV diseases, and consid-
ering the licensed indications for XO inhibitors (manage-
ment of signs and symptoms of primary or secondary gout;
chemotherapy-induced hyperuricemia; and recurrent cal-
cium oxalate stones), we conducted an observational study
among Italian community pharmacies to examine the role
of pharmacists in the detection of inappropriate prescrip-
tions of these drugs.
Methods
Study Design
This study was conducted in Italy between January and
May 2014 among eight community pharmacies distributed
in six different regions. The Study Group of Community
Pharmacists (SGCP) involved eight pharmacists par-
ticipating with an academic master in clinical pharmacies.
The project was divided into two parts: study design and
experimental. During the first part of the study the phar-
macists received training for carrying out the project,
including a standardized procedure for the interviews. Each
pharmacist was asked to interview at least one patient (the
first one with a XO inhibitor prescription) for each week of
the study period. Only users of the drug dispensed were
considered eligible for the study. Patients who met the
inclusion criteria were interviewed with a structured ad hoc
questionnaire with predefined answers at the moment of
drug dispensation. The questionnaire was developed with a
structured consensus development process that included:
evaluation of the evidence; discussion and debate among
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all members; and definition of issues to be investigated.
The consensus process involved two researchers (with
expertise in clinical pharmacology, drug information, and
evidence evaluation) and the community pharmacists
involved in the study, leading to the definition of the ad hoc
questionnaire (see Supplementary Material online).
The pharmacists then completed a standardized, web-
based Case Report Form developed to collect data from all
of the pharmacists involved in the study and facilitate data
analysis. Data collected included sociodemographic
details, drug indication, dosage, body mass index, risk
factors for hyperuricemia (alcohol consumption and red
meat), time since the last gout attack, level of serum uric
acid before drug treatment, duration of drug prescription,
presence of CV diseases, and prescriptions of drugs with
potentially severe drug–drug interactions. All data were
self-reported by the patient and no information was ex-
tracted from a health record completed by the physician.
Only patients who refused the interview were excluded by
the study. No refusal was registered. Data collection
complied fully with Italian laws on personal data protection
and required no ethical committee approval under the
applicable legal principles on patient registries.
Diseases and Drug Appropriateness
The prescription of allopurinol or febuxostat was consid-
ered appropriate according to licensed indications for XO
inhibitors, which include managing the signs and symp-
toms of primary or secondary gout, including gouty
nephropathy, uric acid nephrolithiasis, and other specified
manifestations such as tophi [12]. We also considered the
prescription of allopurinol appropriate in patients with
chemotherapy-induced hyperuricemia. Patients treated for
hyperuricemia but who had no history of a gout attack,
chemotherapy-induced hyperuricemia, or calcium oxalate
stones were considered to be treated for asymptomatic
hyperuricemia. Hyperuricemia was defined as a level of
serum uric acid before drug treatment that was higher than
5.7 mg/dL for women and 7 mg/dL for men.
Statistical Analysis
The sociodemographic characteristics of patients were
described using a univariate analysis (with mean or per-
centage values). Differences in means were tested using the
two-tailed unpaired Student’s t test and the Pearson Chi-
square test for categorical variables. Analyses were done
with JMP Pro 11 (SAS Institute Inc., Cary, NC, USA).
p values less than 0.05 were considered statistically
significant.
Results
The study sample included 74 patients receiving XO
inhibitors. About one third of patients reported a lack of
gout history and had to be treated for asymptomatic
hyperuricemia. No patient was treated for antineoplastic-
induced hyperuricemia. Table 1 summarizes sociodemo-
graphic characteristics of patients interviewed and the
indication of drug treatment. Allopurinol was the XO
inhibitor most frequently prescribed. Febuxostat was pre-
scribed to nine patients: in three patients with a history of
gout, in two patients with uric acid nephrolithiasis, and in
four patients with asymptomatic hyperuricemia. Febuxostat
was prescribed for an expected better efficacy and
tolerability than allopurinol in four patients never treated
with allopurinol: two patients with asymptomatic
hyperuricemia, one patient with gout, and one patient with
uric acid nephrolithiasis.
Twenty-five patients were treated for an unlicensed
indication, reporting to receive the XO inhibitor for
asymptomatic hyperuricemia and in four patients also for
hypertension. Among these patients, information about
serum uric acid levels before treatment was available for
eight male patients: in six patients, the level of serum uric
acid was 7.7–8.2 mg/dL, while in the other two patients the
range was 6.2–6.6 mg/dL. About half of the patients treated
for asymptomatic hyperuricemia had received the drug
treatment for more than 3 years. The duration of XO
treatment is described in Table 2. Patients with asymp-
tomatic hyperuricemia have a higher presence of diabetes
mellitus, obesity, previous myocardial infarction, and heart
failure than patients with an appropriate indication,
although differences were not statistically significant
(Table 3). The interview of each patient took approximately
10 min.
Table 1 Main sociodemographic characteristics of patients receiving
xanthine oxidase inhibitors and drug indications
Variable Value
Patients (n) 74
Age, years, mean (range) 74 (36–98)
Male (%) 43 (58.1)
Patients receiving allopurinol (%) 65 (87.8)
Indication for drugs (%)
Gout 45 (60.8)
Uric acid nephrolithiasis 4 (5.4)
Asymptomatic hyperuricemiaa 25 (33.8)
a All patients had no history of a gout attack
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Discussion
Our study found that community pharmacies could play an
important role in the detection of inappropriate drug pre-
scriptions, suggesting that observational studies conducted
in the community pharmacies could be useful to identify
inappropriate drug use. We found that about one third of
patients receiving XO inhibitors were treated for asymp-
tomatic hyperuricemia and had at least one CV disease,
suggesting an association between inappropriate prescrip-
tion of XO inhibitors and the presence of CV diseases in
hyperuricemic patients. These results are of particular
concern because there is little evidence that allopurinol is
useful in preventing CV diseases [10].
Our findings confirm the results of a recent Italian study
conducted in internal medicine and geriatric wards, which
found that among 4,035 older patients admitted and 3,502
patients discharged only 8.6 and 9.4 % of patients receiv-
ing XO inhibitors were appropriately treated at admission
and discharge, respectively. The study also found that
inappropriate use of XO inhibitors was principally related
to the treatment of asymptomatic hyperuricemia and var-
ious CV diseases [13]. Although conducted in a different
setting with a different population and the differences
between the characteristics of patients with appropriate
indication and asymptomatic hyperuricemia were not sta-
tistically significant, we found a high rate of inappropriate
prescription of XO inhibitors for unlicensed indications.
It has been suggested that allopurinol could be of benefit
in primary prevention of hypertensive and diabetic patients,
especially those with left ventricular hypertrophy, and in
secondary prevention, for acute and chronic myocardial
ischemia, renal failure, cerebral vascular accident, transient
ischemic attack or peripheral artery disease, and heart
failure [14]. Although allopurinol can improve the key
surrogates of endothelial dysfunction, vascular oxidative
stress, myocardial ischemia, and left ventricular mass, and
the pharmacological effects look extremely promising, no
prospective randomized clinical trials have shown CV
benefits in either primary or secondary prevention.
Furthermore, whether lowering serum uric acid will lower
blood pressure remains an unanswered question. Data on
pharmacotherapy for hyperuricemia in hypertension are
limited and restricted to adolescents with recently diag-
nosed, mild essential hypertension [15]. A recent Cochrane
review suggests that there is insufficient evidence to rec-
ommend the use of allopurinol or other hypouricemic drugs
for initial or adjuvant treatment of hypertension and more
randomized clinical trials are needed [16]. In addition, two
recent, genetic, large prospective cohort studies found no
strong evidence for causal relations between uric acid and
ischemic heart disease or blood pressure. However, a
causal effect was found between body mass index, uric acid
level, and hyperuricemia, suggesting that the body mass
Table 2 Distribution of patients receiving xanthine oxidase inhi-
bitors according to indication and duration of treatment
Duration of
treatment









\3 month 3 (6.7) 1 (25.0) 5 (20.0)
3 month to 1 year 3 (6.7) – 4 (16.0)
1–3 years 12 (26.7) – 4 (16.0)
[3 years 27 (60.0) 3 (75.0) 12 (48.0)
Table 3 Characteristics of patients with appropriate and non-appro-







Age, years, mean (range) 75 (36–98) 71 (37–89) 0.13
Male (%) 26 (53.1) 17 (68.0) 0.27




300 mg/day, n (%)
31 (63) 8 (32)
Patients treated with
150 mg/day, n (%)
11 (22) 10 (40)
Patients treated with
100 mg/day, n (%)
2 (4) 2 (8)
Dosage not reported – 1 (4)




150 mg/day, n (%)
– 1 (4)
Patients treated with
80 mg/day, n (%)
4 (8) –
Dosage not reported 1 (2) 3 (12)
Consumption of alcohol 16 (32.7) 12 (48.0) 0.20
Consumption of red meat
([3 times a week)
9 (18.4) 2 (8.0) 0.22
Hypertension (%) 41 (83.7) 17 (68.0) 0.13
Diabetes mellitus (%) 13 (26.5) 9 (36.0) 0.40
Hypercholesterolemia (%) 17 (34.7) 7 (28.0) 0.56
Obesity (%) 11 (22.4) 6 (24.0) 0.81
Previous myocardial
infarction (%)
4 (8.2) 4 (16.0) 0.32
Heart failure (%) 2 (4.1) 2 (8.0) 0.49
At least two cardiovascular
diseasesc
21 (42.8) 12 (48.0) 0.67
a Gout or uric acid nephrolithiasis
b Excluding patients with missing information
c Including diabetes mellitus
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index can act as a confounder in observational associations
and in the development of uric acid-related conditions [17].
Because the information on allopurinol inappropriate
prescription and its consequences is still scant, continuous
surveillance and specific recommendations on appropriate
use could help optimize urate-lowering therapy, targeting
treatment to those who stand to benefit and avoiding
treatment for those who will not [18]. A recent paper from
the Lombardy (Italy) Center for Pharmacovigilance
showed that out of 10 cases of adverse reactions to allop-
urinol reported from September 2012 to September 2013,
seven were severe skin reactions, including Stevens–
Johnson syndrome, and one patient died. In all cases,
allopurinol was not necessary based on current guidelines
for the treatment of asymptomatic hyperuricemia and gout
[18]. In addition, a case of rhabdomyolysis was recently
reported following the administration of febuxostat for
hyperuricemia to a patient with chronic kidney disease
[19]. Bearing in mind that about 5 % of the population and
a quarter of hospitalized patients are hyperuricemic, most
of whom are asymptomatic and will never develop gout,
the treatment of asymptomatic hyperuricemia must be
considered with extreme caution because inappropriate
treatment is clearly unacceptable [10].
Community pharmacies have several roles in promoting
appropriate drug prescriptions: the role of a clinical phar-
macist in medication review has been clearly demonstrated
in older patients who receive repeat prescriptions, where a
pharmacist review of medications resulted in more pre-
scription changes, fewer medications prescribed, and lower
medication costs than did usual general practice [20, 21]. In
England, community pharmacists can provide a wide range
of advanced pharmaceutical services, which include med-
icine use reviews, anticoagulant monitoring services, dis-
ease-specific medicine management services, and many
others. This suggests that pharmacists can be effective in
providing benefits across the range of pharmaceutical care
and even in economic terms [22]. The role in promoting
patient reporting of adverse drug reactions has been
demonstrated by an Italian study conducted among 118
community pharmacies in Veneto [23]. Our study also
suggests that observational studies conducted in commu-
nity pharmacies could contribute to the pharmacovigilance
activity of identifying signals of potentially inappropriate
drug prescriptions and advising physicians to reconsider
the prescription of the drug according to the licensed
indication. Collaborative interventions with general prac-
titioners are, in fact, essential to promote and improve
appropriate drug use. This was recently suggested by a
cluster randomized trial of 303 older long-term users of
benzodiazepines recruited from 30 community pharmacies
in Canada, where community pharmacies contributed to
promote direct patient education to reduce inappropriate
prescriptions of benzodiazepines in older patients [24].
Limitations of the present study include the small
number of patients interviewed and the lack of data about
uric acid levels before the treatment of some hyperuricemic
patients, which limits the possibility of evaluating the use
of allopurinol in patients with asymptomatic hyperuricemia
with a conditional benefit, such as those with persistent
high uric acid level (above 13 mg/dL in men or 10 mg/dL
in women), for the nephrotoxic risks of uric acid [25], or in
those with urinary uric acid excretion exceeding 1,100 mg
daily, which has been associated with a 50 % increase in
the risk of uric acid calculi [26, 27]. Although this
limitation tends to underestimate the appropriate prescrip-
tion of XO inhibitors, for the majority of patients with
hyperuricemia allopurinol is not justified by current evi-
dence [1, 16]. Although our study cannot establish with
certainty a causal relationship between CV diseases and
allopurinol prescription, it does suggest a potential asso-
ciation between allopurinol prescription and the presence
of CV diseases in which clinical benefits of allopurinol are
expected. Another limitation of the study is the lack of data
about patients with severe adverse drug reactions of
allopurinol, which cannot be identified because we inter-
viewed only patients receiving treatment.
Conclusions
Inappropriate use of XO inhibitors is mainly related to the
treatment of asymptomatic hyperuricemia in patients with
no history of gout. Careful assessment of clinical condi-
tions and stricter adherence to evidence-based guidelines
are essential for rational use. Community pharmacists
could contribute to the quality use of drugs, to help con-
sumers better manage their medicine and could have a
great role in identifying signals of potential inappropriate
drug prescriptions. Collaboration between physician and
pharmacists has to evolve in the interest of the quality use
of medicines and improved health outcomes.
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